Arkolith/Insider Trading/OLMA/Form 4

Rappaport Andrew

DirectorOlema Pharmaceuticals, Inc. (OLMA) · full profile →Form 4 · filed Nov 25, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 25, 2025Gift(G)36K—$00
Nov 21, 2025Option exercise(M)36K$0.39$14K36K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 21, 2025Option exercise(M)36K—$00

Transaction Codes

G
Gift
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001162157-25-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML